Budesonide effervescent tablets - Dr Falk Pharma

Drug Profile

Budesonide effervescent tablets - Dr Falk Pharma

Alternative Names: BUET; BUU

Latest Information Update: 04 Feb 2016

Price : $50

At a glance

  • Originator Dr Falk Pharma
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Eosinophilic oesophagitis; Graft-versus-host disease

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 01 Nov 2015 Phase-III clinical trials in Eosinophilic oesophagitis in Germany (Buccal) (NCT02434029)
  • 01 Oct 2015 Dr. Falk Pharm completes a phase III trial in Graft-versus-host (treatment-resistant) disease in Germany and Israel (NCT00887263)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top